Gentian Diagnostics ASA

Gentian Diagnostics launches novel diagnostic test for Inflammation

Moss, 14 July 2017

Gentian Diagnostics AS (OSE: GENT-ME) is pleased to announce the

launch of GCal(Gentian Calprotectin Immunoassay)in countries that

recognize the CE mark. GCal is a novel automated clinical chemistry

blood test used in the diagnosis of inflammation.

The test is CE marked according to the EU directive for in vitro

diagnostic medical devices and will be sold through distributors to

clinical laboratories in Europe. For the rest of the world the test

is only available for research use. Registration activities for

clinical use will now commence in other geographies.

Bård Sundrehagen, CEO of Gentian Diagnostics said, "This test marks

another important milestone for Gentian in our endeavor to broaden

Gentian´s growing range of novel diagnostic tests".

You can read more about GCal on Gentian's website:

http://gentian.no/calprotectin

For further information, please contact:

Bård Sundrehagen

CEO, Gentian Diagnostics AS

Cell Phone: +47 924 14 117

ABOUT GENTIAN DIAGNOSTICS AS

Gentian Diagnostics AS is a medical diagnostics company listed on

Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME".

Gentian is headquartered in Moss, Norway, with a representative

office in China and distribution subsidiaries in Sweden and USA.

Gentian designs, develops and markets in vitro diagnostic reagents

(IVD) based on its proprietary Nanosense technology. The goal is to

offer efficient and accurate reagents for major clinical chemistry

platforms with a focus within the areas of kidney disease, cardiac

disease, inflammation and veterinary medicine. The Nanosense

technology will enable users to move assays from low volume

immunology platforms to fully automated, high throughput instruments

with shorter turnaround times, better workflow and improved cost

efficiency.

AI Terminal